Can women with systemic lupus erythematosus safely use exogenous estrogens?

Jill P. Buyon, Kenneth C. Kalunian, Mary Louise Skovron, Michelle Petri, Robert Lahita, Joan Merrill, Lisa Sammaritano, Christianne Yung, Frederick Licciardi, H. Michael Belmont, Bevra H. Hahn

Research output: Contribution to journalArticle

Abstract

The current study was initiated to estimate the use of oral contraceptives and estrogen replacement therapy in women with systemic lupus erythematosus (SLE). Four hundred and four patients were surveyed from five medical centers. Two hundred and twenty four (55%) had ever used oral contraceptives, however, only 51 (13%) were taking oral contraceptives at the time SLE was diagnosed. Fifty five (14%) used oral contraceptives after their disease was diagnosed. Only seven (13%) reported an exacerbation of disease activity, mostly confined to the musculoskeletal system. In one substudy, there were no significant differences observed between women with or without SLE with regard to the frequency of ever-use of oral contraceptives. In contrast, significantly fewer women with established SLE were taking oral contraceptives at the time of interview compared with healthy women, 0.02. In a second substudy, information on past and present usage of estrogen replacement therapy was obtained in women followed at two of the sites included in the main study. Fifty-five (59%) of the 94 postmenopausal patients at these centers had ever taken estrogen therapy, 23 (24%) at the time of diagnosis. Forty-eight women (51%) began or remained on estrogen therapy after the diagnosis of SLE, four (8%) of whom reported exacerbations of disease activity. A significantly higher percentage of Caucasian women had taken or were taking estrogen replacement compared with other ethnic groups. This study suggests that exogenous hormones were generally well tolerated by women with SLE; this preliminary observation is based on patient recall. The low frequency of current oral contraceptive use in lupus patients of reproductive age may reflect, in part, bias of the managing rheumatologists and obstetricians/gynecologists. Given the health needs of and potential benefits for women with SLE, these observations suggest that larger prospective studies are critical and are likely to change prescribing practices for exogenous estrogen.

Original languageEnglish (US)
Pages (from-to)205-212
Number of pages8
JournalJournal of Clinical Rheumatology
Volume1
Issue number4
StatePublished - 1995

Fingerprint

Systemic Lupus Erythematosus
Estrogens
Oral Contraceptives
Estrogen Replacement Therapy
Disease Progression
Musculoskeletal System
Ethnic Groups
Observation
Hormones
Prospective Studies
Interviews
Health
Therapeutics

Keywords

  • Estrogen replacement
  • Oral contraceptives
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology

Cite this

Buyon, J. P., Kalunian, K. C., Skovron, M. L., Petri, M., Lahita, R., Merrill, J., ... Hahn, B. H. (1995). Can women with systemic lupus erythematosus safely use exogenous estrogens? Journal of Clinical Rheumatology, 1(4), 205-212.

Can women with systemic lupus erythematosus safely use exogenous estrogens? / Buyon, Jill P.; Kalunian, Kenneth C.; Skovron, Mary Louise; Petri, Michelle; Lahita, Robert; Merrill, Joan; Sammaritano, Lisa; Yung, Christianne; Licciardi, Frederick; Belmont, H. Michael; Hahn, Bevra H.

In: Journal of Clinical Rheumatology, Vol. 1, No. 4, 1995, p. 205-212.

Research output: Contribution to journalArticle

Buyon, JP, Kalunian, KC, Skovron, ML, Petri, M, Lahita, R, Merrill, J, Sammaritano, L, Yung, C, Licciardi, F, Belmont, HM & Hahn, BH 1995, 'Can women with systemic lupus erythematosus safely use exogenous estrogens?', Journal of Clinical Rheumatology, vol. 1, no. 4, pp. 205-212.
Buyon JP, Kalunian KC, Skovron ML, Petri M, Lahita R, Merrill J et al. Can women with systemic lupus erythematosus safely use exogenous estrogens? Journal of Clinical Rheumatology. 1995;1(4):205-212.
Buyon, Jill P. ; Kalunian, Kenneth C. ; Skovron, Mary Louise ; Petri, Michelle ; Lahita, Robert ; Merrill, Joan ; Sammaritano, Lisa ; Yung, Christianne ; Licciardi, Frederick ; Belmont, H. Michael ; Hahn, Bevra H. / Can women with systemic lupus erythematosus safely use exogenous estrogens?. In: Journal of Clinical Rheumatology. 1995 ; Vol. 1, No. 4. pp. 205-212.
@article{50fcfc2c5660406a90569f9722b65721,
title = "Can women with systemic lupus erythematosus safely use exogenous estrogens?",
abstract = "The current study was initiated to estimate the use of oral contraceptives and estrogen replacement therapy in women with systemic lupus erythematosus (SLE). Four hundred and four patients were surveyed from five medical centers. Two hundred and twenty four (55{\%}) had ever used oral contraceptives, however, only 51 (13{\%}) were taking oral contraceptives at the time SLE was diagnosed. Fifty five (14{\%}) used oral contraceptives after their disease was diagnosed. Only seven (13{\%}) reported an exacerbation of disease activity, mostly confined to the musculoskeletal system. In one substudy, there were no significant differences observed between women with or without SLE with regard to the frequency of ever-use of oral contraceptives. In contrast, significantly fewer women with established SLE were taking oral contraceptives at the time of interview compared with healthy women, 0.02. In a second substudy, information on past and present usage of estrogen replacement therapy was obtained in women followed at two of the sites included in the main study. Fifty-five (59{\%}) of the 94 postmenopausal patients at these centers had ever taken estrogen therapy, 23 (24{\%}) at the time of diagnosis. Forty-eight women (51{\%}) began or remained on estrogen therapy after the diagnosis of SLE, four (8{\%}) of whom reported exacerbations of disease activity. A significantly higher percentage of Caucasian women had taken or were taking estrogen replacement compared with other ethnic groups. This study suggests that exogenous hormones were generally well tolerated by women with SLE; this preliminary observation is based on patient recall. The low frequency of current oral contraceptive use in lupus patients of reproductive age may reflect, in part, bias of the managing rheumatologists and obstetricians/gynecologists. Given the health needs of and potential benefits for women with SLE, these observations suggest that larger prospective studies are critical and are likely to change prescribing practices for exogenous estrogen.",
keywords = "Estrogen replacement, Oral contraceptives, Systemic lupus erythematosus",
author = "Buyon, {Jill P.} and Kalunian, {Kenneth C.} and Skovron, {Mary Louise} and Michelle Petri and Robert Lahita and Joan Merrill and Lisa Sammaritano and Christianne Yung and Frederick Licciardi and Belmont, {H. Michael} and Hahn, {Bevra H.}",
year = "1995",
language = "English (US)",
volume = "1",
pages = "205--212",
journal = "Journal of Clinical Rheumatology",
issn = "1076-1608",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Can women with systemic lupus erythematosus safely use exogenous estrogens?

AU - Buyon, Jill P.

AU - Kalunian, Kenneth C.

AU - Skovron, Mary Louise

AU - Petri, Michelle

AU - Lahita, Robert

AU - Merrill, Joan

AU - Sammaritano, Lisa

AU - Yung, Christianne

AU - Licciardi, Frederick

AU - Belmont, H. Michael

AU - Hahn, Bevra H.

PY - 1995

Y1 - 1995

N2 - The current study was initiated to estimate the use of oral contraceptives and estrogen replacement therapy in women with systemic lupus erythematosus (SLE). Four hundred and four patients were surveyed from five medical centers. Two hundred and twenty four (55%) had ever used oral contraceptives, however, only 51 (13%) were taking oral contraceptives at the time SLE was diagnosed. Fifty five (14%) used oral contraceptives after their disease was diagnosed. Only seven (13%) reported an exacerbation of disease activity, mostly confined to the musculoskeletal system. In one substudy, there were no significant differences observed between women with or without SLE with regard to the frequency of ever-use of oral contraceptives. In contrast, significantly fewer women with established SLE were taking oral contraceptives at the time of interview compared with healthy women, 0.02. In a second substudy, information on past and present usage of estrogen replacement therapy was obtained in women followed at two of the sites included in the main study. Fifty-five (59%) of the 94 postmenopausal patients at these centers had ever taken estrogen therapy, 23 (24%) at the time of diagnosis. Forty-eight women (51%) began or remained on estrogen therapy after the diagnosis of SLE, four (8%) of whom reported exacerbations of disease activity. A significantly higher percentage of Caucasian women had taken or were taking estrogen replacement compared with other ethnic groups. This study suggests that exogenous hormones were generally well tolerated by women with SLE; this preliminary observation is based on patient recall. The low frequency of current oral contraceptive use in lupus patients of reproductive age may reflect, in part, bias of the managing rheumatologists and obstetricians/gynecologists. Given the health needs of and potential benefits for women with SLE, these observations suggest that larger prospective studies are critical and are likely to change prescribing practices for exogenous estrogen.

AB - The current study was initiated to estimate the use of oral contraceptives and estrogen replacement therapy in women with systemic lupus erythematosus (SLE). Four hundred and four patients were surveyed from five medical centers. Two hundred and twenty four (55%) had ever used oral contraceptives, however, only 51 (13%) were taking oral contraceptives at the time SLE was diagnosed. Fifty five (14%) used oral contraceptives after their disease was diagnosed. Only seven (13%) reported an exacerbation of disease activity, mostly confined to the musculoskeletal system. In one substudy, there were no significant differences observed between women with or without SLE with regard to the frequency of ever-use of oral contraceptives. In contrast, significantly fewer women with established SLE were taking oral contraceptives at the time of interview compared with healthy women, 0.02. In a second substudy, information on past and present usage of estrogen replacement therapy was obtained in women followed at two of the sites included in the main study. Fifty-five (59%) of the 94 postmenopausal patients at these centers had ever taken estrogen therapy, 23 (24%) at the time of diagnosis. Forty-eight women (51%) began or remained on estrogen therapy after the diagnosis of SLE, four (8%) of whom reported exacerbations of disease activity. A significantly higher percentage of Caucasian women had taken or were taking estrogen replacement compared with other ethnic groups. This study suggests that exogenous hormones were generally well tolerated by women with SLE; this preliminary observation is based on patient recall. The low frequency of current oral contraceptive use in lupus patients of reproductive age may reflect, in part, bias of the managing rheumatologists and obstetricians/gynecologists. Given the health needs of and potential benefits for women with SLE, these observations suggest that larger prospective studies are critical and are likely to change prescribing practices for exogenous estrogen.

KW - Estrogen replacement

KW - Oral contraceptives

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=0000471033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0000471033&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 205

EP - 212

JO - Journal of Clinical Rheumatology

JF - Journal of Clinical Rheumatology

SN - 1076-1608

IS - 4

ER -